Arnhold LLC Purchases 106,267 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Arnhold LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 16.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 758,746 shares of the biopharmaceutical company’s stock after purchasing an additional 106,267 shares during the period. Pfizer accounts for 2.0% of Arnhold LLC’s holdings, making the stock its 17th biggest position. Arnhold LLC’s holdings in Pfizer were worth $20,130,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PFE. Norges Bank bought a new stake in shares of Pfizer during the 4th quarter worth $2,328,986,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $274,694,000. Massachusetts Financial Services Co. MA boosted its stake in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. grew its holdings in Pfizer by 1,106.0% during the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after buying an additional 5,153,257 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday. They issued a “neutral” rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.57.

View Our Latest Analysis on Pfizer

Pfizer Price Performance

Shares of Pfizer stock opened at $22.80 on Friday. The firm has a market cap of $129.31 billion, a PE ratio of 16.17, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company’s fifty day simple moving average is $24.63 and its two-hundred day simple moving average is $26.01. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.54%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).